Gastrointestinal stromal tumor – A review of clinical studies

Abstract

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. With the advent of Imatinib, the treatment of gastrointestinal stromal tumor has been revolutionized as both the progression-free and overall survival rates have increased dramatically. Unfortunately, gastrointestinal stromal tumor patients on Imatinib do eventually fail due to resistance. Even though sunitinib and regorafenib have been shown to be highly effective as second- and third-line treatments, both have limited effects. New treatments are highly warranted for this reason. In this present review, 25 registered pharmacological clinical trials at ClinicalTrials.gov have been reviewed and show promising and encouraging results.

Keywords

Clinical trials gastrointestinal stromal tumor (GIST)resistance

Get full access to this article

View all access options for this article.

References

Mazur

Clark

. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507–519.

Zhao

Yue

. Gastrointestinal stromal tumor. J Gastrointest Oncol 2012; 3: 189–208.

Miettinen

Lasota

. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 2001; 438: 1–12.

Hirota

Isozaki

Moriyama

et al.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–580.

Joensuu

Roberts

Sarlomo-Rikala

et al.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–1056.

Demetri

von Mehren

Blanke

et al.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Engl J Med 2002; 347: 472–480.

Dagher

Cohen

Williams

et al.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034–3038.

Heinrich

Corless

Duensing

et al.

PDGFRA Activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–710.

Subramanian

West

Corless

et al.

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004; 23: 7780.

10.

Corless

Schroeder

Griffith

et al.

PDGFRA Mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357–5364.

11.

Heinrich

Corless

Demetri

et al.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342–4349.

12.

Yim

Cho

et al.

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor. Korean J Int Med 2018; 33: 432–434.

13.

Boikos

Pappo

Killian

et al.

Molecular subtypes of kit/pdgfra wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic. JAMA Oncol 2016; 2: 922–928.

14.

Wang

C-M

Huang

Zhou

et al.

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol 2010; 136: 1065–1071.

15.

Heinrich

Rankin

Blanke

et al.

Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 swog intergroup trial s0033. JAMA Oncol 2017; 3: 944–952.

16.

Casali

Abecassis

Bauer

et al.

Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2018; 29(Supplement_4): iv68–iv78.

17.

Demetri

van Oosterom

Garrett

et al.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329–1338.

18.

Demetri

Reichardt

Kang

Y-K

et al.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295–302.

19.

Goodman

Rock

Dagher

et al.

Approval Summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367–1373.

20.

Leach B. Regorafenib approved to treat GIST, www.onclive.com/web-exclusives/regorafenib-approved-to-treat-gist (2013, Accessed 25 December 2018).

21.

Viergever

. Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open 2015; 5: e008932.

22.

ClinicalTrials.gov. Clinical trials, https://clinicaltrials.gov/ (accessed 31 December 2018).

23.

ClinicalTrials.gov. Regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor, https://clinicaltrials.gov/ct2/show/NCT01068769 (2018, accessed 1 January 2019).

24.

George

Wang

Heinrich

et al.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401–2407.

25.

Ben-Ami

Barysauskas

von Mehren

et al.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol 2016; 27: 1794–1799.

26.

ClinicalTrials.gov. Phase Ib study of sunitinib alternating with regorafenib in patients with metastatic and/or unresectable GIST (SURE), https://clinicaltrials.gov/ct2/show/NCT02164240 (2018, accessed 11 January 2019).

27.

ClinicalTrials.gov. A randomised trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST) (ALT GIST), https://clinicaltrials.gov/ct2/show/NCT02365441 (2016, accessed 1 January 2019).

28.

ClinicalTrials.gov. A study of famitinib in patients with gastrointestinal stromal tumor, https://clinicaltrials.gov/ct2/show/NCT02336724 (2018, accessed 11 January 2019).

29.

ClinicalTrials.gov. PLX9486 as a single agent and in combination with PLX3397 or PLX9486 with sunitinib in patients with advanced solid tumors, https://clinicaltrials.gov/ct2/show/NCT02401815 (2018, accessed 11 January 2019).

30.

ClinicalTrials.gov. Randomized trial of crenolanib in subjects with D842V mutated GIST, https://clinicaltrials.gov/ct2/show/NCT02847429 (2018, accessed 11 January 2019).

31.

ClinicalTrials.gov. (NAVIGATOR) Study of BLU-285 in patients with gastrointestinal stromal tumors (GIST) and other relapsed and refractory solid tumors, https://clinicaltrials.gov/ct2/show/NCT02508532 (accessed 11 January 2019).

32.

ClinicalTrials.gov. (VOYAGER) Study of avapritinib vs. regorafenib in patients with locally advanced unresectable or metastatic GIST, https://clinicaltrials.gov/ct2/show/NCT03465722 (accessed 11 January 2019).

33.

ClinicalTrials.gov. A safety, tolerability and PK study of DCC-2618 in patients with advanced malignancies, https://clinicaltrials.gov/ct2/show/study/NCT02571036 (2018, accessed 11 January 2019).

34.

Janku

Heinrich

Razak

et al.

Abstract CT029: pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST). Cancer Res 2018; 78(13 Supplement): CT029–CT029.

35.

ClinicalTrials.gov. Phase 3 study of DCC-2618 vs placebo in advanced GIST patients who have been treated with prior anticancer therapies (invictus), https://clinicaltrials.gov/ct2/show/NCT03353753 ( 2018, accessed 21 January 2019).

36.

ClinicalTrials.gov. A study of DCC-2618 vs sunitinib in advanced gist patients after treatment with imatinib (intrigue), https://clinicaltrials.gov/ct2/show/NCT03673501 (2018, accessed 21 January 2019).

37.

ClinicalTrials.gov. Ipilimumab and imatinib mesylate in treating participants with metastatic or unresectable solid tumors, https://clinicaltrials.gov/ct2/show/NCT01738139 (2018, accessed 21 January 2019).

38.

Reilley

Bailey

Subbiah

et al.

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 2017; 5: 35.

39.

ClinicalTrials.gov. Nivolumab and ipilimumab in treating patients with rare tumors, https://clinicaltrials.gov/ct2/show/NCT02834013 (2018, accessed 21 January 2019).

40.

ClinicalTrials.gov. A study to evaluate the safety of intuvax administered intra-tumorally in patients with gastrointestinal stromal tumors (GIST), https://clinicaltrials.gov/ct2/show/NCT02686944 (2018, accessed 21 January 2019).

41.

ClinicalTrials.gov. Epacadostat and pembrolizumab in patients with GIST, https://clinicaltrials.gov/ct2/show/NCT03291054 (2018, accessed 22 January 2019).

42.

ClinicalTrials.gov. A study of XmAb®18087 in subjects with NET and GIST, https://clinicaltrials.gov/ct2/show/NCT03411915 (2018, accessed 21 January 2019).

43.

ClinicalTrials.gov. PDR001 plus imatinib for metastatic or unresectable GIST, https://clinicaltrials.gov/ct2/show/NCT03609424 (2018, accessed 21 January 2019).

44.

ClinicalTrials.gov. A study of AUY922 for GIST (Gastrointestinal Stromal Tumor) patients, https://clinicaltrials.gov/ct2/show/NCT01389583 (2015, accessed 21 January 2019).

45.

Bendell

Bauer

Lamar

et al.

A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors. Cancer Invest 2016; 34: 265–270.

46.

ClinicalTrials.gov. Efficacy and safety of PD-0332991 in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib (CYCLIGIST), https://clinicaltrials.gov/ct2/show/NCT01907607 (2017, accessed 21 January 2019).

47.

ClinicalTrials.gov. MEK162 in combination with imatinib mesylate in patients with untreated advanced gastrointestinal stromal tumor (GIST), https://clinicaltrials.gov/ct2/show/NCT01991379 (2018, accessed 21 January 2019).

48.

ClinicalTrials.gov. A study of MEK162 (Binimetinib) in combination with pexidartinib in patients with advanced gastrointestinal stromal tumor (GIST), https://clinicaltrials.gov/ct2/show/NCT03158103 (2018, accessed 22 January 2019).

49.

ClinicalTrials.gov. BGJ398 in combination with imatinib mesylate in patients with untreated advanced gastrointestinal stromal tumor (GIST), https://clinicaltrials.gov/ct2/show/NCT02257541 (2018, accessed 21 January 2019).

50.

Kelly

Shoushtari

Qin

L-X

et al.

A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Invest New Drugs 2019; 37: 282–290.

51.

ClinicalTrials.gov. Study of the glutaminase inhibitor CB-839 in solid tumors, https://clinicaltrials.gov/ct2/show/NCT02071862 (2018, accessed 11 January 2019).

52.

ClinicalTrials.gov. A study of BBI503 in adult patients with advanced gastrointestinal stromal tumors, https://clinicaltrials.gov/ct2/show/NCT02232620 (2018, accessed 22 January 2019).

53.

ClinicalTrials.gov. A study of LY2880070 in participants with advanced or metastatic cancer, https://clinicaltrials.gov/ct2/show/NCT02632448 (accessed 22 January 2019).

54.

ClinicalTrials.gov. Temozolomide (TMZ) in advanced succinate dehydrogenase (SDH)-mutant/deficient gastrointestinal stromal tumor (GIST), https://clinicaltrials.gov/ct2/show/NCT03556384 (2018, accessed 22 January 2019).

55.

Havemann

Wolf

Holle

et al.

Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987; 59: 1072–1082.

56.

Fisher

DeVITA

Hubbard

et al.

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Int Med 1983; 98: 304–309.

57.

Romaguera

Fayad

Rodriguez

et al.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023.

58.

Kim

S-M

Chang

H-J

et al.

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer. BMC Cancer 2018; 18: 956.

59.

Nakata

Ijichi

Hanai

et al.

Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: a multi-institutional phase II study. Auris Nasus Larynx 2017; 44: 104–110.

60.

Zhou

Zhang

Chang

et al.

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol 2013; 72: 1043–1053.

61.

Le Cesne

Blay

J-Y

Bui

et al.

Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010; 46: 1344–1351.

62.

Judson

Demetri

. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 2007; 18(Suppl_10): x20–x24.

63.

Wagner

Tap

Shields

et al.

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST). J Clin Oncol 2018; 36(15_suppl): 11509.

64.

Gebreyohannes

Burton

Wozniak

et al.

PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. Clin Exp Med 2019; 19: 201–210.

65.

Heinrich

Griffith

McKinley

et al.

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012; 18: 4375–4384.

66.

Indio

Astolfi

Tarantino

et al.

Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene. Int J Mol Sci 2018; 19: 732.

67.

Gebreyohannes

Wozniak

Zhai

M-E

et al.

Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res 2019; 25: 609–618.

68.

Singh

Chmielowski

Hecht

et al.

A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST). J Clin Oncol 2018; 36(4_suppl): 55–55.

69.

Mitchell

Hamid

Smith

et al.

Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol 2018; 36: 3223–3230.

70.

Lee

S-H

Chu

Rashid

et al.

Anti-SSTR2× anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: a potential immunotherapy for neuroendocrine tumors. Am Assoc Cancer Res 2017; 77. (13_suppl): abstract 3633.

71.

Naing

Gelderblom

Gainor JF et al.

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors. J Clin Oncol 2016; 34(15_suppl): 3060–3060.

72.

Florou

Wilky

Trent

. Latest advances in adult gastrointestinal stromal tumors. Future Oncol 2017; 13: 2183–2193.

73.

Finn

Dering

Conklin

et al.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77.

74.

Fry

Harvey

Keller

et al.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Therap 2004; 3: 1427–1438.

75.

Dickson

Tap

Keohan

et al.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31: 2024.

76.

Chi

Qin

L-X

D'Angelo

et al.

A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). J Clin Oncol 2015; 33(15_suppl): 10507–10507.

77.

Kim

Cavnar

Cohen

et al.

Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res 2014; 20: 2350–2362.

78.

Ascierto

Schadendorf

Berking

et al.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013; 14: 249–256.

79.

Finn

Javle

Tan

et al.

A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. J Clin Oncol 2012; 30(Suppl 4): a220.

80.

Tannir

Fan

Lee

et al.

Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). J Clin Oncol 2018; 36(6_suppl): 603–603.

81.

FDA. FDA Grants Fast Track Designation to Calithera Biosciences’ CB-839, www.fdanews.com/articles/182210-fda-grants-fast-track-designation-to-calithera-biosciences-cb-839 (2017, accessed 26 January 2019).

82.

Bardsley

Horváth

Asuzu

et al.

Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139: 942–952.

83.

Sakurikar

Eastman

. Will targeting Chk1 have a role in the future of cancer therapy?. J Clin Oncol 2015; 33: 1075–1077.

84.

Lee

Nair

Zimmer

et al.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol 2018; 19: 207–215.

85.

Trent

Beach

Burgess

et al.

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98: 2693–2699.

86.

Miettinen

Lasota

. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – a review. Int J Biochem Cell Biol 2014; 53: 514–519.